China Sky One has 11 generics in pipeline

US-listed drugmaker China Sky One Medical says that it has 11 new generic products entering clinical trials in China, including seven administered by injection, an area into which the company is expanding.

The generic candidates are: povidone iodine suppository, for the treatment of moniliasis colpitis, bacterial colpitis, and hemorrhoids; gabexate mesylate injection, for acute pancreatitis and hemorrhagic necrosis of the pancreas; ciclopirox ointment, for superficial fungal infection; ciclopirox olamine vaginal suppositories, for moniliasis or mycotic colitis; fibrauretnire suppositories, for vulvar moniliasis vaginosis; omeprazole sodium injection, for digestive ulcers, gastrinoma, stress ulcers and reflux esophagitis; ozagrel sodium injection, for acute cerebral infarction; citicoline sodium injection, for acute brain injury and postoperative consciousness impediment; tiopronin injection, for the improvement of liver function; carbazochrome sodium sulfonate injection, to treat the urinary system, upper digestive tract, respiratory system and obstetric hemorrhage; and diltiazem HCl injection, for paroxysmal supraventricular tachycardia and unstable angina pectoris.

Yan-Qing Liu, chief executive of the firm, said of the drugs: "we are confident that they can expand our market share and increase profitability going forward. Our move into the injectable drug delivery market represents a strong opportunity for future growth since the traditional injection is still a dominant delivery method. The testing for these drugs needs about six months to complete and [we will] submit them to the State Food and Drug Administration for approval in the beginning of 2009," he explained.